J&J Tops Q4 Adjusted Earnings Estimates, But 2025 Sales Outlook Falls Short
1. JNJ's Q4 sales met estimates at $22.52 billion. 2. Net income of $3.43 billion fell below analyst expectations. 3. Adjusted profits surpassed estimates at $4.94 billion. 4. 2025 revenue projections are below current analyst expectations. 5. Pharmaceuticals and medical technology sales grew by 4.4% and 6.7%.